NRGene Technologies Ltd.
NRGN | TA
Overview
Corporate Details
- ISIN(s):
- IL0011720716
- LEI:
- Country:
- Israel
- Address:
- 5 Golda Meir Street, 7403649 Ness Ziona
- Website:
- https://nrgene.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Nrgene offers advanced genomics and data analysis tools for agricultural research, helping improve crop yields and sustainability in Israel.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for NRGene Technologies Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2023-08-09 20:13 |
Regulatory News Service
Following the completion of its contracted two-year engagement under the Tel Av…
|
Hebrew (modern) | 174.5 KB | |
| 2023-08-09 20:13 |
Business and Financial Review
Following the completion of its contracted two-year engagement under the Tel Av…
|
Russian | 46.0 KB | |
| 2023-05-22 23:48 |
Management Discussion and Analysis
Analysis update report, target price remains 19.8 NIS
|
English | 969.2 KB | |
| 2023-05-22 23:48 |
Earnings Release
Analysis update report, target price remains 19.8 NIS
|
Russian | 70.9 KB | |
| 2023-04-13 20:31 |
Earnings Release
Analysis update - target price t is updated to NIS 19.8
|
English | 959.3 KB | |
| 2023-04-13 20:31 |
Regulatory News Service
Analysis update - target price t is updated to NIS 19.8
|
Russian | 67.3 KB | |
| 2022-12-11 20:51 |
Business and Financial Review
Analysis update report, target price remains 30.9NIS
|
English | 1.1 MB | |
| 2022-12-11 20:51 |
Report Publication Announcement
Analysis update report, target price remains 30.9NIS
|
Russian | 64.0 KB | |
| 2022-09-13 22:01 |
Investor Presentation
update Analysis (FROST) following financial report, target price remains NIS 30…
|
English | 1.2 MB | |
| 2022-09-13 22:01 |
Report Publication Announcement
update Analysis (FROST) following financial report, target price remains NIS 30…
|
Russian | 60.5 KB | |
| 2022-08-15 21:22 |
Investor Presentation
Investors Presentation - August 2022
|
English | 2.5 MB | |
| 2022-08-15 21:22 |
Report Publication Announcement
Investors Presentation - August 2022
|
Russian | 41.9 KB | |
| 2022-05-31 21:47 |
Investor Presentation
Analysis update report, target price remains 30.9NIS
|
English | 1.1 MB | |
| 2022-05-31 21:47 |
Report Publication Announcement
Analysis update report, target price remains 30.9NIS
|
Russian | 55.2 KB | |
| 2022-04-03 22:30 |
Regulatory News Service
Quarterly analysis update report, target price remains 30.9NIS
|
English | 1.1 MB |
Automate Your Workflow. Get a real-time feed of all NRGene Technologies Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for NRGene Technologies Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nortem BioGroup | Spain | MLBIO | |
|
Novo Nordisk | Denmark | NOVO | |
|
NUFORMIX PLC | United Kingdom | NFX | |
|
Nykode Therapeutics ASA | Norway | NYKD | |
|
Oculis Holding AG | Switzerland | OCS | |
|
ONCODESIGN | France | ALONC | |
|
Oncodesign Precision Medicine S.A | France | ALOPM | |
|
Oncoinvent ASA | Norway | OCIN | |
|
Oncopeptides | Sweden | ONCO | |
|
Onxeo | France | ALONX |